Loncar China BioPharma ETF
CHNA
CHNA was delisted on the 20th of October, 2023.
4 hedge funds and large institutions have $631K invested in Loncar China BioPharma ETF in 2021 Q2 according to their latest regulatory filings, with 3 funds opening new positions, 0 increasing their positions, 0 reducing their positions, and 3 closing their positions.
0% more funds holding
Funds holding: 4 → 4 (0)
0% more first-time investments, than exits
New positions opened: 3 | Existing positions closed: 3
2.92% less ownership
Funds ownership: 6.23% → 3.32% (-2.9%)
31% less capital invested
Capital invested by funds: $920K → $631K (-$289K)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
FEM
Fulcrum Equity Management
Plano,
Texas
|
+$413K |
| 2 |
Osaic Holdings
Scottsdale,
Arizona
|
+$39K |
| 3 |
MCM
MV Capital Management
Bethesda,
Maryland
|
+$16.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Jane Street
New York
|
-$773K |
| 2 |
UBS Group
Zurich,
Switzerland
|
-$62K |
| 3 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$4K |
CHNA Hedge Fund Activity: Q2 2021 in Review
4 of the 5,767 institutional investors tracked by Wall St. Rank reported a position in Loncar China BioPharma ETF (CHNA) for Q2 2021, worth a combined $631K — down 31% from $920K a quarter earlier.
Fund positioning in CHNA was balanced in Q2 2021: 3 funds opened new positions, 3 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was Fulcrum Equity Management, opening a new position worth an estimated $413K. The largest seller was Jane Street, exiting entirely with an estimated $773K sold.
- 4 institutional investors held Loncar China BioPharma ETF (CHNA) as of Q2 2021, unchanged from Q1 2021.
- Funds reported $631K of Loncar China BioPharma ETF stock for Q2 2021, down 31% quarter-over-quarter.
- 3 funds opened new Loncar China BioPharma ETF positions in Q2 2021 and 3 closed out, a net change of 0 holders.
- The largest Loncar China BioPharma ETF buyer in Q2 2021 was Fulcrum Equity Management, an estimated $413K added.
- The largest Loncar China BioPharma ETF seller in Q2 2021 was Jane Street, an estimated $773K sold.
Based on aggregated 13F filings for Q2 2021.